ArticleJournal of cannabis research2026
Not what it seems: analytical validation and label accuracy of commercial CBD oils using HPTLC.
Article in Journal of cannabis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The rapid growth of the cannabidiol (CBD) market has raised concerns about product labeling accuracy and quality control. This study aimed to validate a high-performance thin-layer chromatography (HPTLC) method and apply it to analyze CBD content in commercial oils and e-liquids available in Costa Rica. The HPTLC method was validated following guidelines of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. Performance parameters assessed included linearity, accuracy, precision, specificity, and limits of detection (LOD), and quantification (LOQ). After validation, the method was used to quantify CBD and screen for other phytocannabinoids such as CBG, CBN, and Δ⁹-THC in 5 commercial oils and 3 e-liquids. The method showed excellent linearity (R² > 0.9998), precision (%CV < 2%), and accuracy (99–102% recovery), while successfully detecting CBD concentrations and qualitatively identifying other cannabinoids. Notably, some commercial samples showed CBD over- and underlabeling, and tentative presence of Δ⁹-THC. These findings reveal inconsistencies between the labeled and actual CBD content in several products, mirroring international trends, and represent the first documented evidence of mislabeling in hemp-based products in Costa Rica. The validated HPTLC method offers a cost-effective tool for regulatory surveillance, enabling preliminary cannabinoid profiling and quantification. Its application can support public health policies and consumer protection through improved product transparency and compliance with Costa Rica’s national hemp regulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.